ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Faliang Xing

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5073635824. Sources: OpenAlex.

Their work

Papers: 5 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 17

Papers, trials and grants by year

2023: 1 paper · 2024: 2 papers · 2025: 2 papers

Papers 5

G3BP2 promotes tumor progression and gemcitabine resistance in PDAC via regulating PDIA3-DKC1-hENT in a stress granules-dependent manner. Co-author DOI 10.1038/s41401-024-01387-5 ↗
Global burden of early-onset pancreatic cancer attributable to metabolic risks from 1990 to 2021, and projections to 2030. Co-author DOI 10.3389/fonc.2025.1660313 ↗
Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer. Co-author DOI 10.1007/s12033-023-00875-z ↗
YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer. First author DOI 10.1016/j.canlet.2024.217197 ↗
Stress granules dynamics and promising functions in pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2023.188885 ↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jin Xu · 2 shared papers, 2023–2024 · strength 0.52
- Paper Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer. DOI 10.1007/s12033-023-00875-z ↗
- Paper Stress granules dynamics and promising functions in pancreatic cancer. DOI 10.1016/j.bbcan.2023.188885 ↗
Yi Qin · 2 shared papers, 2023–2024 · strength 0.52
- Paper Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer. DOI 10.1007/s12033-023-00875-z ↗
- Paper Stress granules dynamics and promising functions in pancreatic cancer. DOI 10.1016/j.bbcan.2023.188885 ↗
Bo Zhang · 2 shared papers, 2024–2025 · strength 0.51
- Paper Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer. DOI 10.1007/s12033-023-00875-z ↗
- Paper Global burden of early-onset pancreatic cancer attributable to metabolic risks from 1990 to 2021, and projections to 20… DOI 10.3389/fonc.2025.1660313 ↗
Yingjin Fang · 2 shared papers, 2025 · strength 0.48
- Paper G3BP2 promotes tumor progression and gemcitabine resistance in PDAC via regulating PDIA3-DKC1-hENT in a stress granules… DOI 10.1038/s41401-024-01387-5 ↗
- Paper Global burden of early-onset pancreatic cancer attributable to metabolic risks from 1990 to 2021, and projections to 20… DOI 10.3389/fonc.2025.1660313 ↗
Xianjun Yu · 2 shared papers, 2024–2025 · strength 0.42
- Paper Global burden of early-onset pancreatic cancer attributable to metabolic risks from 1990 to 2021, and projections to 20… DOI 10.3389/fonc.2025.1660313 ↗
- Paper YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic… DOI 10.1016/j.canlet.2024.217197 ↗
Wei Wang · 1 shared paper, 2024 · strength 0.28
- Paper Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer. DOI 10.1007/s12033-023-00875-z ↗
Xian-Jun Yu · 1 shared paper, 2025 · strength 0.25
- Paper G3BP2 promotes tumor progression and gemcitabine resistance in PDAC via regulating PDIA3-DKC1-hENT in a stress granules… DOI 10.1038/s41401-024-01387-5 ↗
Bo Zhang · 1 shared paper, 2025 · strength 0.25
- Paper G3BP2 promotes tumor progression and gemcitabine resistance in PDAC via regulating PDIA3-DKC1-hENT in a stress granules… DOI 10.1038/s41401-024-01387-5 ↗
Bo Zhang · 1 shared paper, 2023 · strength 0.24
- Paper Stress granules dynamics and promising functions in pancreatic cancer. DOI 10.1016/j.bbcan.2023.188885 ↗
Qingcai Meng · 1 shared paper, 2025 · strength 0.23
- Paper Global burden of early-onset pancreatic cancer attributable to metabolic risks from 1990 to 2021, and projections to 20… DOI 10.3389/fonc.2025.1660313 ↗
Chen Liang · 1 shared paper, 2025 · strength 0.23
- Paper Global burden of early-onset pancreatic cancer attributable to metabolic risks from 1990 to 2021, and projections to 20… DOI 10.3389/fonc.2025.1660313 ↗
Xiaowu Xu · 1 shared paper, 2024 · strength 0.20
- Paper YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic… DOI 10.1016/j.canlet.2024.217197 ↗
Borui Li · 1 shared paper, 2024 · strength 0.20
- Paper YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic… DOI 10.1016/j.canlet.2024.217197 ↗
Chenjie Zhou · 1 shared paper, 2024 · strength 0.20
- Paper YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic… DOI 10.1016/j.canlet.2024.217197 ↗
Zheng Li · 1 shared paper, 2024 · strength 0.20
- Paper YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic… DOI 10.1016/j.canlet.2024.217197 ↗
Qifeng Zhuo · 1 shared paper, 2024 · strength 0.20
- Paper YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic… DOI 10.1016/j.canlet.2024.217197 ↗
Shunrong Ji · 1 shared paper, 2024 · strength 0.20
- Paper YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic… DOI 10.1016/j.canlet.2024.217197 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.